TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11488772
Drug: Adrenomedullin (ADM)
Normalized name: THP-Adm
DrugBank: Adrenomedullin (DB19102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenomedullin (ADM) infusion (1-30 pmol x min(‐1))
Study: 11488772
Drug: Proadrenomedullin N‐terminal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proadrenomedullin N‐terminal 20 peptide (PAMP) infusion (100-3000 pmol x min(‐1))
Study: 11488772
Drug: Adrenomedullin (ADM)
Normalized name: THP-Adm
DrugBank: Adrenomedullin (DB19102)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenomedullin (ADM) co-infused with NEP inhibitor thiorphan (30 nmol x min(‐1))
Study: 9138439
Drug: Intravenous pentagastrin
Normalized name: pentagastrin
DrugBank: Pentagastrin (DB00183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous pentagastrin
Study: 3046645
Drug: Aspirin (330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (330 mg three times a day) plus dipyridamole (75 mg three times a day) for a mean of 25 months, with warfarin for three months.
Study: 3046645
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for a mean of 23 months, with warfarin for three months.
Study: 29805116
Drug: Elobixibat 10
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat 10 mg/day for 2 weeks
Study: 29805116
Drug: Elobixibat (varied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elobixibat (varied doses: 5 mg/day, 10 mg/day, or 15 mg/day) for 52 weeks
Study: 28277886
Drug: Endometrin® 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrin® 200 mg/day (Group A)
Study: 28277886
Drug: Endometrin® 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrin® 300 mg/day (Group B)
Study: 28277886
Drug: Endometrin® 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endometrin® 200 mg/day (control group)
Study: 26194656
Drug: Bupivacaine 0.25
Normalized name: levobupivacaine 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25 % (40 ml)
Study: 26194656
Drug: Levobupivacaine 0.25
Normalized name: levobupivacaine 0.25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.25 % (40 ml)
Study: 21923426
Drug: Formoterol 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 24 μg
Study: 10912983
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 400 microg
Study: 12004271
Drug: Drugs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with DLHigh
Study: 12004271
Drug: Drugs with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs with DLLow
Study: 12004271
Drug: Each active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each active drug with DLHigh
Study: 12004271
Drug: Each active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each active drug with DLLow
Study: 12004271
Drug: No drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drugs with IQ > median
Study: 12004271
Drug: One drug
Normalized name: mometasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drug with IQ > median
Study: 12004271
Drug: Two drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two drugs with IQ > median
Study: 12004271
Drug: Three drugs
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three drugs with IQ > median
Study: 12004271
Drug: Four or
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four or five drugs with IQ > median
Study: 7605186
Drug: Intravenous orphenadrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous orphenadrine citrate (60mg)
Study: 2189123
Drug: Beta-carotene supplementation
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene supplementation (0, 15, 30, or 60 mg daily for six months)
Study: 478162
Drug: Domperidone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone (20 mg t.d.s before meals)
Study: 29498351
Drug: High-Ca fat-free
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Ca fat-free milk phase (MD) - approximately 1500 mg of Ca/d
Study: 29498351
Drug: Low-Ca phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Ca phase (CD) - approximately 800 mg of Ca/d
Study: 26224203
Drug: CYP2C19 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CYP2C19 inhibitors (felbamate, oxcarbazepine)
Study: 26224203
Drug: Concomitant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of AEDs that are either CYP450 inhibitors or inducers with clobazam
Study: 17109385
Drug: IGIV-C (Gamunex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C (Gamunex, 10%) infused at 0.08 mL/kg/min
Study: 17109385
Drug: IGIV-C (Gamunex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C (Gamunex, 10%) infused at 0.11 mL/kg/min
Study: 17109385
Drug: IGIV-C (Gamunex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C (Gamunex, 10%) infused at 0.14 mL/kg/min
Study: 17109385
Drug: IGIV-C (Gamunex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C (Gamunex, 10%) at all infusion rates
Study: 17109385
Drug: IGIV-C (Gamunex,
Approvals — FDA: no, EMA: no, PMDA: no
Description: IGIV-C (Gamunex, 10%) at 0.14 mL/kg/min
Study: 11862176
Drug: Silon-TSR (Bio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silon-TSR (Bio Med Sciences) followed by Aquaphor ointment
Study: 2237768
Drug: Sequential gradient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential gradient intermittent pneumatic compression applied for 4 hours each day.
Study: 2237768
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment with ulcer debridement, cleaning, nonadherent dressing, and graduated compression stockings).
Study: 31374367
Drug: Comprehensive assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive assessments (Functional Assessment of Cancer Therapy-Gynecologic Oncology Group/Neurotoxicity questionnaire)
Study: 28957556
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (infliximab or prednisone and SSZ)
Study: 25692241
Drug: Dinoprostone (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (3 mg)
Study: 23645763
Drug: Historical control
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical control of weekly docetaxel regimen
Study: 20680427
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBOT) at 24% oxygen at 1.3 ATA for 40 sessions
Study: 12590402
Drug: Amitriptyline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (75 mg/day)
Study: 19444001
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Amitriptyline 75 mg/day and Fluvoxamine 100 mg/day)
Study: 9475648
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (5 mL x kg(‐1) every 30 min)
Study: 8582538
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion (10% triglyceride emulsion) at a rate of 0.4 ml/min with heparin (200 U bolus followed by 0.2 U/min per kg body weight) for 24 hours
Study: 8582538
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion (10% triglyceride emulsion) for 24 hours
Study: 8582538
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0.9% NaCl infusion)
Study: 8582538
Drug: Recovery test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recovery test after discontinuation of Intralipid infusion
Study: 2215098
Drug: Lidocaine group
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine group (2 mL 4% lidocaine solution injected through the catheter)
Study: 380941
Drug: Methylprednisolone sodium
Normalized name: methylPREDNISolone sodium phosphate
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone sodium succinate (MPSS), 30 mg/kg
Study: 380941
Drug: Dexamethasone sodium
Normalized name: dexamethasone sodium phosphate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone sodium phosphate (DSP), 6 mg/kg
Study: 31003229
Drug: OnabotulinumtoxinA (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA (additional injections into toe muscles: flexor digitorum longus, flexor hallucis longus)
Study: 26903253
Drug: Integrative Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Group Therapy for SMD, 11-week duration, participants stabilized on psychostimulant medication.
Study: 26903253
Drug: Community-based psychosocial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based psychosocial treatment, control group.
Study: 17595241
Drug: 1700 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1700 mg/d metformin treatment for 6 months
Study: 17595241
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) administered using a traditional incremental-dose protocol for 6 months
Study: 9764962
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg oral dose of tacrine
Study: 7942079
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive treatment
Study: 31593756
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy (HF) - 64.6 Gy in 19 fractions
Study: 31593756
Drug: Conventionally fractionated
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventionally fractionated radiation therapy (CF) - 78.0 Gy in 39 fractions
Study: 29393690
Drug: 600 µg
Normalized name: P.G. 600 KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 µg vaginal misoprostol 6 hours before IUD insertion
Study: 24622517
Drug: Continue hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continue hormone therapy (HT+)
Study: 24622517
Drug: Discontinue hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discontinue hormone therapy (HT-)
Study: 24622517
Drug: Concurrent progestins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent progestins with either 17βE or CEE
Study: 23527013
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation 400 IUs daily for 2 months
Study: 23527013
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation 2000 IUs daily for 2 months
Study: 23527013
Drug: Baseline vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline vitamin D deficiency (25(OH)D<20 ng/ml)
Study: 17440528
Drug: Plant sterol-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol-rich diet (2 g/day sitosterol)
Study: 17440528
Drug: Plant sterol-rich
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol-rich diet (1 g/day sitosterol)
Study: 10972368
Drug: Nifedipine 30
Normalized name: nifedipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 30 mg (long-acting gastrointestinal-transport-system formulation)
Study: 10972368
Drug: Co-amilozide (hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amilozide (hydrochlorothiazide 25 mg plus amiloride 2.5 mg)
Study: 8797136
Drug: Dolasetron mesylate
Normalized name: Dolasetron Mesylate
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dolasetron mesylate (1.2, 1.8, and 2.4 mg/kg i.v.)
Study: 8797136
Drug: Ondansetron (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (32 mg i.v.)
Study: 8459374
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of droperidol, hyoscine, and metoclopramide in subtherapeutic doses
Study: 8459374
Drug: Droperidol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (1.25 mg) alone
Study: 3080868
Drug: Intralipid (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid (50 g soya oil emulsified with egg lecithin)
Study: 3080868
Drug: Lipofundin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipofundin (50 g soya oil emulsified with soya lecithin)
Study: 26988798
Drug: Arjuna extract
Normalized name: Terminalia arjuna whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arjuna extract 750 mg twice daily
Study: 23444397
Drug: ERN/LRPT (extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN/LRPT (extended release niacin 2 g plus laropiprant 40 mg daily)
Study: 21253392
Drug: Cholecalciferol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily
Study: 21253392
Drug: Cholecalciferol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily + sodium fluoride (25 mg bid)
Study: 21253392
Drug: Cholecalciferol (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (1000 IU) and calcium citrate (800 mg) daily + ibandronate (1 mg iv/3‐monthly)
Study: 10744088
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg alosetron
Study: 10886042
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg alosetron
Study: 1397674
Drug: 75 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/kg captopril
Study: 1397674
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day enalapril
Study: 1397674
Drug: 30 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/day delapril hydrochloride
Study: 28614793
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of CBD
Study: 29635142
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for panic disorder (PD)
Study: 26714287
Drug: Standard, body-weight-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard, body-weight-based tacrolimus dosing
Study: 22572418
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg once weekly)
Study: 22572418
Drug: Oral penicillin
Normalized name: penicillin G Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral penicillin (phenoxy methyl penicillin 250 mg twice daily)
Study: 20840200
Drug: Brief treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief treatment (two-session)
Study: 20840200
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment (nine-session)
Study: 18047921
Drug: telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: telmisartan 40 mg/day
Study: 18047921
Drug: valsartan 80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: valsartan 80 mg/day
Study: 16231111
Drug: Chlorhexidine gel
Normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine gel (Chlorhexamed) for 15 minutes (3 x 5 min) every 12 weeks
Study: 16231111
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish (Fluoridin) applied to all teeth 4 and 8 weeks after CHX treatments
Study: 8750365
Drug: Ramipril-chlorthalidone combination
Normalized name: Ramipril
DrugBank: Ramipril (DB00178)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ramipril-chlorthalidone combination treatment (5 mg + 25 mg)
Study: 8750365
Drug: Chlorthalidone monotherapy
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone monotherapy (25 mg daily)
Study: 29693757
Drug: Adjunctive probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive probiotics (Lactobacillus rhamnosus strain GG and Bifidobacterium animalis subsp. lactis strain Bb12)
Study: 29693757
Drug: Adjunctive probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive probiotics
Study: 17663737
Drug: YM150 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: YM150 3 mg
Study: 9928755
Drug: Bendrofluazide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide 2.5 mg once daily
Study: 6756418
Drug: Niludipine 20
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niludipine 20 mg, 4 times a day
Study: 6756418
Drug: Niludipine 60
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niludipine 60 mg
Study: 6756418
Drug: Niludipine 60
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niludipine 60 mg in normotensives
Study: 6756418
Drug: Niludipine +
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niludipine + Propranolol 10 mg, 4 times a day
Study: 6756418
Drug: Niludipine +
Normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niludipine + Propranolol + Penfluzide 2.5 mg a day
Study: 22662740
Drug: Telephone-delivered cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered cognitive-behavioral therapy (CBT)
Study: 19654139
Drug: Bone-marrow-derived stem
Normalized name: Bone-marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-marrow-derived stem cells (BMSC) administered by intracoronary infusion
Study: 19654139
Drug: Bone-marrow-derived stem
Normalized name: Bone-marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone-marrow-derived stem cells (BMSC) delivered by intra-myocardial injection
Study: 17617290
Drug: Generic terazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic terazosin (2 mg/d for 2 weeks, then adjusted to 1 mg/d or 4 mg/d)
Study: 17617290
Drug: Branded terazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branded terazosin (2 mg/d for 2 weeks, then adjusted to 1 mg/d or 4 mg/d)
Study: 14694168
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone plus oral prednisone
Study: 11576413
Drug: 0.1% mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% mometasone furoate ointment
Study: 11576413
Drug: 0.005% fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% fluticasone proprionate ointment
Study: 11576413
Drug: Wet wraps
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wet wraps with either ointment after 2 weeks
Study: 2656860
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg (11 patients) and 25 mg (1 patient) twice daily for 4 weeks
Study: 19750263
Drug: Extra parenteral
Normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra parenteral fluid therapy (group I)
Study: 9307346
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin (2-g dose every 6 hours) and erythromycin (250-mg dose every 6 hours) for 48 hours followed by oral amoxicillin (250-mg dose every 8 hours) and erythromycin base (333-mg dose every 8 hours) for 5 days
Study: 9307346
Drug: Intravenous ampicillin
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ampicillin and erythromycin
Study: 8103875
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (SK) 1.5 MU
Study: 3734034
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (400 mg acute administration)
Study: 3734034
Drug: RU 486
Normalized name: RUS 3108
DrugBank: RUS 3108 (DB05911)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RU 486 (400 mg daily for 3 days)
Study: 28695791
Drug: L+Z supplementation
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L+Z supplementation (12 mg/daily)
Study: 22507791
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents targeting different pathways such as lenalidomide
Study: 22507791
Drug: New monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: New monoclonal antibodies
Study: 22507791
Drug: Bruton’s tyrosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bruton’s tyrosine kinase inhibitor
Study: 12809395
Drug: Chest tubes
Normalized name: Kids-Eeze Chest Relief
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chest tubes removed at the second postoperative day when drainage output declined to less than 50 mL in a five-hour period.
Study: 31907007
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) of infliximab
Study: 31907007
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with infliximab without knowledge of drug levels or ADAb status
Study: 23770919
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection with 400 μg cobalamin
Study: 21386706
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with amlodipine/valsartan (10/320 mg)
Study: 21386706
Drug: Moderate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate treatment with amlodipine/valsartan (5/160 mg)
Study: 21386706
Drug: Moderate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate treatment